LLY-284 is the less potent diastereomer of the potent SAM-competitive PRMT5 inhibitor
LLY-283 (IC50 = 20 nM against PRMT5-catalyzed methylation of an H4R3-derived peptide substrate) and an ideal control compound for cellular studies. For characterization details of the active probe, LLY-283, please visit the
LLY-283 probe summary on the Structural Genomics Consortium (SGC) website.
LLY-283, the active probe, is available from Sigma. To learn more about and purchase LLY-283,
click here.
To learn about other SGC chemical probes for epigenetic targets, visit
sigma.com/sgc